Retatrutide Availability & Timeline

Each trial in the TRIUMPH program serves a specific purpose. The FDA needs data across different patient populations to feel confident that the drug is both safe and effective broadly, not just in one narrow group.

TRIUMPH-1 and TRIUMPH-2 are the pivotal trials. "Pivotal" means the FDA considers their results the primary evidence for an approval decision. Both are expected to report results by mid-2026. Without positive results from these two trials, the entire timeline shifts later. With positive results, Eli Lilly can begin assembling the application immediately.

The head-to-head trial against tirzepatide (NCT06662383) is particularly interesting. This is the first trial directly comparing retatrutide and tirzepatide in 800 patients under identical conditions. Results are expected in December 2026. For an existing comparison based on separate trials, see our retatrutide vs tirzepatide analysis.

The Phase 2 trial published in the New England Journal of Medicine in June 2023 was what put retatrutide on the map. In that trial, 338 adults with obesity received weekly injections for 48 weeks. People on the highest dose (12 mg) lost 24.2% of their body weight. Some participants lost over 30% (Jastreboff et al., NEJM 2023).

That was Phase 2, designed mainly to figure out the right dose and confirm the drug actually works. Phase 3 extends the testing to larger groups, longer durations, and more diverse patient populations. The TRIUMPH-4 result of 28.7% at 68 weeks exceeded the Phase 2 result, suggesting the effect strengthens with longer treatment.

A substudy within the Phase 2 trial also found that retatrutide reduced liver fat by up to 82% in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called fatty liver disease. That reduction occurred within 48 weeks and exceeded the results of any other drug tested for that condition (Sanyal et al., NEJM 2024). For a deeper look at the mechanism behind these results, see how does retatrutide work.

Eli Lilly needs final data from TRIUMPH-1 (2,300 obesity patients) and TRIUMPH-2 (1,000 type 2 diabetes patients). These are the trials the FDA will scrutinize most closely. Both are expected to deliver top-line results around the middle of 2026.

"Top-line results" means the key findings: did people lose significantly more weight than placebo, and was the drug safe enough? The detailed analysis, including subgroup breakdowns, long-term safety data, and secondary endpoints, takes additional months to compile.

Based on TRIUMPH-4 and Phase 2 data, analysts widely expect positive results. But biology can surprise. If a serious safety signal emerges in a larger population, the timeline could extend by a year or more. In the Phase 3 TRIUMPH-4 trial, a new safety signal called dysesthesia (abnormal skin sensations like tingling or burning) appeared in up to 20.9% of patients on the highest dose. The FDA will want to understand this signal fully before approving the drug. For details on known side effects, see our retatrutide side effects guide.

After the pivotal trials finish, Eli Lilly assembles a New Drug Application (NDA). This is a massive document, sometimes exceeding 100,000 pages, that contains every piece of data the FDA needs to evaluate the drug: efficacy results, safety data, manufacturing details, proposed labeling, and the plan for post-approval monitoring.

Preparing an NDA typically takes 4 to 6 months after the last pivotal trial reports. Analysts expect Lilly to submit in late 2026, possibly Q4. The company has not publicly confirmed a submission date, but its quarterly investor calls have consistently described retatrutide as a "late-stage pipeline priority."

Lilly could also pursue a pre-NDA meeting with the FDA, where the agency provides informal guidance on what the application should contain. This meeting helps avoid last-minute surprises that could delay the review. Given the scale and importance of the TRIUMPH program, a pre-NDA meeting is almost certain.

Once the FDA accepts the NDA for review, it has 10 months for a Standard Review or 6 months for a Priority Review. Priority Review is granted when a drug represents a "significant improvement" over existing treatments.

Does retatrutide qualify for Priority Review? There is a strong argument that it does. No approved drug produces 28.7% weight loss. The closest, tirzepatide, peaks around 22.5%. That 6-percentage-point gap is clinically meaningful, representing an additional 15 to 20 pounds of weight loss for the average patient. The liver fat reduction data and potential cardiovascular benefits add further justification.

However, the FDA has been cautious with weight loss drugs historically. The agency may want the full 10-month Standard Review to thoroughly examine the dysesthesia signal and the cardiovascular safety data from TRIUMPH-3. If TRIUMPH-3 is not complete by the time of submission, the FDA may require Lilly to submit that data as a post-marketing commitment, which would allow approval to proceed but with conditions.

If Lilly submits in Q4 2026 and receives Standard Review, the FDA decision would come around August to October 2027. With Priority Review, the decision could arrive as early as April to June 2027.

The FDA sometimes convenes an independent panel of outside experts, called an Advisory Committee, to publicly debate whether a drug should be approved. These meetings are not mandatory. The FDA skipped the advisory committee for tirzepatide's obesity indication (Zepbound) in 2023, approving it directly.

For retatrutide, an advisory committee meeting is possible but not certain. The dysesthesia safety signal and the novel triple-agonist mechanism might prompt the FDA to seek external input. If scheduled, the meeting typically occurs 1 to 2 months before the approval decision date (called the PDUFA date). The committee's recommendation is non-binding but almost always followed.

Advisory committees rarely derail drugs that have strong efficacy data. The bigger risk is a "complete response letter," where the FDA asks for additional data or changes before granting approval. This would push the timeline back by 6 to 12 months. Complete response letters have become uncommon for obesity drugs with large, well-run trial programs (FDA CDER Annual Reports).

FDA approval is not the same as pharmacy availability. After approval, Eli Lilly needs to manufacture enough supply, negotiate insurance coverage, set up distribution, and train healthcare providers on the new drug. Based on how Lilly launched Zepbound (tirzepatide for weight loss), this ramp-up takes 2 to 4 months.

Zepbound was approved on November 8, 2023, and was available at pharmacies within a few weeks. But it took months for insurance coverage to expand, and supply shortages persisted into 2024. Lilly has learned from that experience and is likely investing in manufacturing capacity for retatrutide well ahead of approval.

The cost at launch will likely mirror Zepbound's pricing: approximately $1,000 to $1,100 per month before insurance. Eli Lilly typically offers manufacturer savings cards that can reduce the out-of-pocket cost to $25 per month for eligible patients. Use our peptide cost calculator to compare current options. For details on insurance dynamics, see tirzepatide cost with insurance.

Novo Nordisk began the STEP clinical trial program for semaglutide (Wegovy) in 2018. The STEP 1 trial published results in the New England Journal of Medicine in February 2021, showing 14.9% weight loss at 68 weeks (Wilding et al., NEJM 2021).

The NDA for Wegovy was submitted in December 2020, before the pivotal trial was even published. The FDA approved Wegovy on June 4, 2021, using Priority Review. Total time from first Phase 3 enrollment to approval: roughly 3 years. However, supply shortages delayed widespread availability until late 2023.

For a look at semaglutide results, see semaglutide before and after.

Eli Lilly started the SURMOUNT trial program for tirzepatide in late 2020. SURMOUNT-1 published in the New England Journal of Medicine in July 2022, showing 22.5% weight loss at 72 weeks (Jastreboff et al., NEJM 2022).

Lilly submitted the NDA for Zepbound in mid-2023 and received FDA approval on November 8, 2023. Total time from first Phase 3 enrollment to approval: roughly 3 years. Unlike semaglutide, Zepbound was available at pharmacies within weeks of approval, though supply constraints persisted for months.

For dosing guidance on tirzepatide, see how long does tirzepatide take to work.

Both semaglutide and tirzepatide took approximately 3 years from first Phase 3 enrollment to FDA approval. The TRIUMPH program began enrolling in mid-2023. Applying the same 3-year window points to mid-2026 at the earliest and mid-2027 as the more realistic target.

Lilly has one advantage this time: institutional experience. The company navigated the tirzepatide approval process just two years ago. The regulatory team, manufacturing infrastructure, and commercial playbook are already in place. This could shave a few months off the timeline, particularly in the NDA preparation and launch phases.

The potential delay factor is the triple-agonist novelty. Semaglutide and tirzepatide had predecessor drugs in their same class that the FDA had already reviewed (liraglutide and native GIP, respectively). Retatrutide's glucagon component is new territory for the agency. The FDA may take extra time to evaluate the glucagon-related safety signals, particularly the heart rate increase (up to 6.7 bpm above baseline) and dysesthesia (Nature Medicine, 2024).

Phase 2 tested retatrutide in 338 people. That is enough to confirm the drug works but not enough to catch rare side effects that might affect 1 in 500 or 1 in 1,000 patients. The Phase 3 TRIUMPH program enrolls over 5,800 people specifically to find those rare events.

Consider the math. A side effect that occurs in 0.1% of patients (1 in 1,000) has only a 28% chance of appearing in a 338-person trial. In a 5,800-person program, that same side effect has a 99.7% chance of being detected. The FDA wants that 99.7% confidence level before 50 million Americans start taking a new weight loss drug (FDA Guidance on Clinical Trial Size).

The dysesthesia signal illustrates why this matters. It was barely noticeable in Phase 2 but appeared in up to 20.9% of patients on the highest dose in Phase 3. Without the larger trial, this side effect might not have been characterized until after millions of people were already taking the drug.

Every currently approved weight loss drug works through GLP-1 alone (semaglutide) or GLP-1 plus GIP (tirzepatide). Retatrutide adds glucagon receptor activation, something no approved drug does. The FDA has no direct precedent for reviewing a glucagon agonist for chronic weight management.

Glucagon's primary natural role is raising blood sugar when it drops too low. A drug that activates glucagon receptors carries theoretical risks: it could raise fasting blood sugar, accelerate muscle protein breakdown, or overstimulate the heart. In the clinical trials so far, blood sugar effects have been manageable (retatrutide actually improved blood sugar in diabetic patients), and muscle loss has been proportional to weight loss. The heart rate increase of 4 to 7 beats per minute is within acceptable range but requires monitoring (Coskun et al., Nature 2022).

The FDA will want long-term cardiovascular data to confirm that the heart rate increase does not translate into higher rates of heart attacks or strokes. TRIUMPH-3 (the cardiovascular outcomes trial with 1,800 patients) is designed to answer exactly this question. For a comparison of retatrutide vs tirzepatide including safety profiles, see our dedicated analysis.

Retatrutide is a 39-amino-acid synthetic peptide with a fatty acid modification that extends its half-life. Manufacturing peptides at pharmaceutical scale is technically challenging. Each amino acid must be added in precise sequence, the fatty acid must be attached at the correct position, and the final product must be purified to greater than 99% purity (Lau & Dunn, Bioorganic & Medicinal Chemistry 2018).

Eli Lilly invested $4 billion in expanding its manufacturing facilities in 2024 and 2025, partly in anticipation of retatrutide demand. The company opened a new facility in Lebanon, Indiana, and expanded its Research Triangle Park site in North Carolina. These investments suggest Lilly is confident in approval and is building capacity ahead of it.

Manufacturing bottlenecks delayed semaglutide (Wegovy) availability for over two years after approval. Lilly appears determined to avoid repeating that mistake with retatrutide. For context on current peptide sourcing, see where to buy peptides in 2026 and peptide sciences alternatives.

Enrolling in a TRIUMPH trial is the only way to receive pharmaceutical-grade retatrutide under medical supervision. Everything is free: the drug, doctor visits, lab work, and monitoring. You may receive placebo (an inactive injection), but even placebo participants get extensive medical care throughout the study.

To find active trials near you, go to ClinicalTrials.gov and search for "retatrutide," or visit Eli Lilly's trial finder at trials.lilly.com. General eligibility requirements include a BMI of 30 or higher (or 27+ with a weight-related health condition), age 18 or older, and no history of pancreatitis or medullary thyroid carcinoma.

As of March 2026, two trials are actively recruiting new participants: the Maintenance trial (NCT06859268, testing dose reduction after initial weight loss) and a new enrollment trial (NCT07232719, 250 participants with obesity or overweight). Competition for spots is intense. Apply early and be prepared for a screening process that typically takes 2 to 4 weeks.

If you have a life-threatening obesity-related condition, have exhausted all approved treatments, and cannot enroll in a clinical trial, your doctor can request expanded access directly from Eli Lilly. Call 1-800-545-5979. The company responds within 5 business days.

This pathway is extremely narrow. Being overweight, even severely overweight, typically does not qualify. You would need complications like severe heart failure, respiratory failure, or organ damage directly attributable to obesity. Fewer than 1% of requests are granted for experimental weight loss drugs.

Some online vendors sell retatrutide labeled "for research use only, not for human consumption." These products are not manufactured to pharmaceutical standards, are not inspected by the FDA, and their purity varies widely between suppliers.

The FDA has taken aggressive enforcement action against peptide vendors since 2024. Over 50 warning letters were issued to GLP-1 compounders in September 2025 alone. Peptide Sciences, one of the largest research vendors, shut down voluntarily in early 2026. The legal and safety landscape for research peptides is increasingly hostile. For the full regulatory picture, see FDA peptide crackdown 2026.

If you choose to go this route, understand the quantified risks. A 2024 FDA investigation of seized GLP-1 peptide samples found that 15% contained bacterial endotoxins exceeding safety limits. Another 8% had purity below 90%, meaning up to 10% of the vial contained unknown impurities. Some samples contained heavy metals including lead and cadmium at levels exceeding USP limits (FDA Consumer Update, 2025). For general safety guidance, see our peptide safety guide.

Zepbound (tirzepatide for weight loss) launched at $1,059.87 per month. Mounjaro (tirzepatide for diabetes) was priced at $1,023.04 per month. Retatrutide will almost certainly fall in a similar range, possibly slightly higher given the additional receptor target and superior efficacy data.

For context, Wegovy (semaglutide for weight loss) costs $1,349.02 per month. Ozempic (semaglutide for diabetes) costs $935.77 per month. Weight loss drugs from the same manufacturer tend to be priced at a premium over diabetes versions of similar drugs.

Use the peptide cost calculator to compare costs across available options.

Insurance coverage for weight loss drugs remains inconsistent. As of early 2026, most commercial insurance plans cover Mounjaro (diabetes indication) but fewer cover Zepbound (weight loss indication). Medicare does not cover any weight loss drugs.

Legislation is moving in the right direction. The Treat and Reduce Obesity Act has been reintroduced in Congress multiple times, and some state Medicaid programs have begun covering GLP-1 agonists for obesity. By the time retatrutide reaches market in late 2027 or 2028, coverage may have expanded significantly.

Eli Lilly will almost certainly offer a manufacturer savings card for retatrutide, similar to the Zepbound savings card that reduces the monthly cost to $25 for commercially insured patients. These programs typically exclude government insurance (Medicare, Medicaid, Tricare). For a breakdown of current insurance dynamics, see tirzepatide cost with insurance.

Not legally. US law only permits compounding of drugs that are already FDA-approved and either on the drug shortage list or not commercially available in a needed form. Retatrutide has never been approved, so there is no legal basis for compounding it.

Even after approval, compounding would only be permitted if retatrutide entered the FDA's drug shortage list, which happened with both semaglutide and tirzepatide. Lilly's manufacturing investments suggest the company is trying to avoid shortage scenarios. For background on the compounding landscape, see is compound tirzepatide safe and compound semaglutide with B12.

True generic competition is even further away. Eli Lilly's patents on retatrutide extend into the 2040s. A generic version would require those patents to expire or be successfully challenged, plus a separate FDA approval process for the generic. You should not expect a generic retatrutide for at least 15 years after initial approval.

Two effective weight loss drugs are available by prescription right now. Tirzepatide (sold as Zepbound for weight loss) targets two of the three receptors that retatrutide hits and produces about 22.5% body weight loss. Semaglutide (sold as Wegovy for weight loss) targets one receptor and produces about 15% loss.

Starting one of these medications today does not prevent you from switching to retatrutide later. Both tirzepatide and retatrutide are made by Eli Lilly, and the transition would involve a standard dose titration protocol. See our retatrutide dosage guide for how titration works. For guidance on transitioning between GLP-1 drugs, see semaglutide to tirzepatide switching.

Your doctor can help determine which option fits your medical history, insurance coverage, and goals. If cost is a barrier, manufacturer savings cards can reduce Zepbound to $25 per month for eligible patients. For injection technique, see how to inject tirzepatide.

Two TRIUMPH trials are still recruiting as of March 2026. The maintenance trial (NCT06859268) tests whether patients can reduce their retatrutide dose after achieving significant weight loss. The new enrollment trial (NCT07232719) has 250 spots for adults with obesity or overweight.

Search for open trials at ClinicalTrials.gov or trials.lilly.com. Be prepared to provide your BMI, medical history, and current medications during the screening process. If your nearest trial site is far away, some trials cover travel expenses. Ask the study coordinator when you call.

Weight loss drugs produce better outcomes when combined with behavioral changes. Clinical trials require participants to follow a reduced-calorie diet and increase physical activity, and the weight loss numbers reflect that combination. The drug alone produces less.

Start tracking measurable health markers now: weight, waist circumference, blood pressure, fasting blood sugar, and cholesterol. This creates a baseline so you can accurately measure the impact of any treatment you eventually start. It also documents your weight management efforts, which insurance companies and clinical trials look for.

For broader guidance on beginning a peptide-based protocol, see getting started with peptides. For preparation and storage fundamentals, see how to store peptides and how to reconstitute retatrutide.

Breakthrough Therapy Designation. If the FDA grants this designation (which it has not yet), Lilly would receive more intensive FDA guidance and a potentially faster review. The 28.7% weight loss and 82% liver fat reduction could justify this designation, particularly for MASLD, which currently has limited treatment options.

Positive TRIUMPH-1 and TRIUMPH-2 results. If both pivotal trials deliver results as strong as or stronger than TRIUMPH-4, Lilly could submit the NDA as early as Q3 2026 rather than Q4, shaving 1 to 3 months off the timeline.

Rolling submission. The FDA sometimes allows companies to submit sections of the NDA as they become ready, rather than waiting for the complete application. This can save 2 to 4 months. Lilly used this approach with tirzepatide.

Safety signals in larger trials. If TRIUMPH-1 or TRIUMPH-2 reveal a new safety concern not seen in smaller trials, the FDA could require additional studies. The dysesthesia signal from TRIUMPH-4 is already on the agency's radar. If the rate or severity increases in larger populations, it could prompt a complete response letter.

Manufacturing delays. Peptide manufacturing at pharmaceutical scale is technically demanding. If Lilly encounters production problems, it could delay the launch even after approval. The company's $4 billion manufacturing investment is designed to prevent this, but technical issues can still arise.

Regulatory environment changes. The FDA's approach to obesity drugs has been evolving. A change in FDA leadership, new safety requirements, or shifts in regulatory philosophy could add review time. The current FDA commissioner has been supportive of obesity drug development, but political changes are unpredictable.

Complete response letter. If the FDA issues a complete response letter (asking for more data rather than approving), the delay is typically 6 to 12 months. This happened to lorcaserin (Belviq) and naltrexone/bupropion (Contrave) before their eventual approvals.

Eli Lilly typically files for European approval (through the EMA's centralized procedure) around the same time as the FDA submission, sometimes within a few months. The EMA review process takes approximately 12 to 15 months, longer than the FDA. If Lilly files with both agencies in late 2026, European approval could come in early to mid-2028.

However, individual European countries then negotiate pricing and reimbursement, which adds another 6 to 18 months before the drug is actually available at pharmacies in each country. UK approval through the MHRA may come separately and could be faster since Brexit allowed the UK to conduct independent reviews.

Japan, Australia, Canada, and several other countries have their own approval pathways. Japan's PMDA often requires Japan-specific clinical data, which could delay approval there. Australia's TGA and Canada's Health Canada sometimes rely on FDA or EMA reviews to expedite their own processes.

The bottom line: if you are outside the United States, expect retatrutide availability 6 to 18 months after FDA approval, depending on your country's regulatory timeline and Lilly's submission strategy.

Eli Lilly is also developing orforglipron, an oral (pill) GLP-1 agonist. In Phase 3 trials, orforglipron produced approximately 12 to 14% weight loss. That is less than injectable retatrutide but comes in a pill format that many patients prefer over weekly injections. Orforglipron is on a similar timeline to retatrutide, with potential approval in 2027 or 2028.

Lilly may position retatrutide as the maximum-efficacy injectable option and orforglipron as the more convenient oral option, giving doctors and patients a choice within Lilly's own portfolio.

Novo Nordisk, the maker of Ozempic and Wegovy, is developing amycretin, a dual GLP-1 and amylin agonist. Early data showed approximately 22% weight loss in 36 weeks, which extrapolates to potentially 25% or more at 68 weeks. This positions amycretin as a direct competitor to retatrutide, likely reaching market around the same time.

The existence of multiple competitors is actually good for patients. Competition typically drives prices down, expands insurance coverage, and gives doctors more options to match individual patient needs. For a perspective on existing drug comparisons, see retatrutide vs tirzepatide.

Survodutide is a dual GLP-1 and glucagon agonist (it skips GIP). Phase 2 results showed approximately 19% weight loss at 46 weeks. This drug targets the same glucagon receptor as retatrutide but without the GIP component. If survodutide reaches market before retatrutide, it could provide early real-world evidence on glucagon receptor safety, which would benefit the retatrutide review process.